Burke Neurological Institute (BNI) is deeply saddened by the passing of an incredibly kind and thoughtful colleague, Dr. M. Flint Beal. As one of the greatest clinician-scientists of his generation, Dr.
Today, scientists still do not know the cause of Alzheimer’s disease (AD), yet decades of research advancements give hope to the possibility of slowing down early-onset of AD. Benfotiamine, a therapeutic drug that raises blood vitamin B1, levels very high, was recently tested as a pilot clinical study conducted by the Gibson Lab at the Burke Neurological Institute.
Benfotiamine and Cognitive Decline in Alzheimer's Disease, a small exploratory clinical trial, conducted by Dr. Gary E. Gibson’s laboratory at the Burke Neurological Institute is listed in CNN Health’s article on ”Top 2020 health stories you may have missed because of Covid-19” under Advances in Alzheimer’s.
A small exploratory clinical trial conducted by Dr. Gary E. Gibson’s laboratory at the Burke Neurological Institute in collaboration with physicians at the Burke Rehabilitation Hospital, suggests that Benfotiamine is safe and potentially efficacious in improving cognitive outcomes among people living with Mild Cognitive Impairment and mild Alzheimer’s disease (AD).
Burke Neurological Institute is pleased to share our highlights and impacts achieved during 2019. Together, we renew hope to those living with neurological disabilities by helping people to see, remember, talk, write, and walk again. Enjoy these accomplishments from 2019 as we look forward to a bright 2020!
Burke Neurological Institute is very grateful to our Board of Trustees, faculty, staff, patients, families, and friends. Thank you for bringing our mission to life and for supporting our efforts to advance the Science that Hope Demands!
Burke Neurological Institute invites interested and qualified undergraduate students to apply to our Summer Science Research Program. The 10-week program will run from June through August 2019. Learn more >